Finanzas de Sophia Genetics SA (SOPH)SOPHSophia Genetics SA

Evaluating the bottom line, SOPHiA GENETICS SA maintains a gross margin of 64.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.27%, while the net margin is -95.91%. These profitability ratios, combined with a Return on Equity (ROE) of -101.22%, provide a clear picture of how effectively SOPH converts its operational activities into shareholder value.

In the context of the broader market, SOPH competes directly with industry leaders such as CCSI and SPT. With a market capitalization of $692.94M, it holds a significant position in the sector. When comparing efficiency, SOPH's gross margin of 64.61% stands against CCSI's 79.98% and SPT's 77.59%. Such benchmarking helps identify whether SOPHiA GENETICS SA is trading at a premium or discount relative to its financial performance.

SOPH has shown a significant increase in revenue, with Q2 2026 revenue at $23.3 million, surpassing expectations. However, it continues to report net losses, with a net income of -22.36 million in Q2 2026.